6-K 1 c98391.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ------------ FORM 6-K ------------ REPORT OF FOREIGN ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 May 2, 2008 ------------ NOVO NORDISK A/S (Exact name of Registrant as specified in its charter) NOVO ALLE DK-2880, BAGSVAERD DENMARK (Address of principal executive offices) ------------ Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F [X] Form 40-F [ ] Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes [ ] No [X] If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____________________ TREASURY STOCK NOVO NORDISK A/S - SHARE REPURCHASE PROGRAMME On 31 January 2008 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no. 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. Under the programme Novo Nordisk will repurchase B shares for an amount of up to DKK 2 billion in the period from 31 January 2008 to 6 August 2008. Since the announcement as of 21 April 2008, the following transactions have been made under the programme: NUMBER OF AVERAGE TRANSACTION SHARES PURCHASE PRICE VALUE, DKK ACCUMULATED, LAST 2,707,907 884,996,948 ANNOUNCEMENT 21 April 2008 100,000 321.8500 32,185,000 22 April 2008 50,000 315.3500 15,767,500 23 April 2008 60,000 308.3200 18,499,440 24 April 2008 50.000 315.4000 15.770.000 25 April 2008 50,000 319.3700 15,968,500 ACCUMULATED, 2008 3,017,907 983,187,388 With the transactions stated above, Novo Nordisk owns a total of 27,977,880 treasury shares, corresponding to 4.3% of the share capital. The total amount of shares in the company is 646,960,000 including treasury shares. Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,000 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com. Further information: Media: Investors: Outside North America: Outside North America: Elin K Hansen Mads Veggerby Lausten Tel: (+45) 4442 3450 Tel: (+45) 4443 7919 ekh@novonordisk.com mlau@novonordisk.com Hans Rommer Tel: (+45) 4442 4765 hrmm@novonordisk.com In North America: In North America: Sean Clements Christian Qvist Frandsen Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937 secl@novonordisk.com cqfr@novonordisk.com Stock Exchange Announcement no 23 / 2008 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized. Date: May 2, 2008 NOVO NORDISK A/S --------------------------------------------------- Lars Rebien Sorensen, President and Chief Executive Officer